FILTER
FILTERED INTERVIEW RESULTS
Denis Dufrane
CO-FOUNDER AND CEO, NOVADIP
"I believe 2023 and 2024 will be key for Novadip. We have already closed two trials in the autologous program. We are now in Phase 1/2 trials for CPT in young patients, both in the US and in Europe."
Jeff Butler
PRESIDENT, AMPAC FINE CHEMICALS
"AFC’s core technology differentiators include energetic chemistry, high potency manufacturing, and extensive chromatographic separation capabilities."
Tyrone Brewer
PRESIDENT, US ONCOLOGY, JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
"I am excited about Janssen’s aspirational vision to eliminate cancer. With targeted therapies and immunotherapies, cancer treatment can be more effective and less toxic, enabling individuals to manage their disease while also maintaining their quality of life."
Joe Panetta
PRESIDENT AND CEO, BIOCOM CALIFORNIA
"The lifecycle of new product introduction into the market will now be shorter, as companies have fewer years to recover revenue as a result of the IRA."
Andrea Confetti & Roberto Fanelli
EXCLUSIVE SYNTHESIS BUSINESS UNIT LEADER (AC) & CATALOGUE APIS BU DEPUTY MANAGER (RF), DIPHARMA FRANCIS
RF: "Our experience in developing proprietary chemical processes and alternative solutions to support the generic API industry has been instrumental in rapidly expanding our CDMO activities."
Daniel Palmacci
PRESIDENT, CELL & GENE DIVISION, LONZA
"We want to give patients the best access to the amazing technology and treatments being developed by cell and gene therapy innovators. This is the modality with the greatest potential in the healthcare industry today."
John Patrick Oroho
PRESIDENT AND GENERAL MANAGER, PORZIO LIFE SCIENCES
"We are always looking at new regulations in the US and worldwide: laws very seldom change incrementally, so we adapt our systems to reflect that."
Michael Quirmbach
CEO AND PRESIDENT, CORDENPHARMA
"Our main mission is the execution of a >€200 million investment into CapEx projects that will bring additional capacity and technologies online to support pharma and biotech customers as their drug development projects progress."
Christiana Bardon
CO-MANAGING PARTNER, MPM | BIOIMPACT CAPITAL
"We see this as an exciting time to be investing in record-high levels of innovation at very attractive valuations."
Debbie Hart
PRESIDENT AND CEO, BIONJ
"To ensure that New Jersey maintains this leadership position, BioNJ will continue to work with State government to support industry and stave off onerous proposals. "
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
